India approves Covishield, Covaxin for emergency use

New Delhi: Two of the leading coronavirus vaccine contenders in India have been granted approval for restricted use.

Oxford-AstraZeneca's coronavirus vaccine Covishield, manufactured by Serum Institute of India and Bharat Biotech's COVID vaccine Covaxin have been approved for emergency use authorisation.

The Drug Controller General of India V.G Somani said that the Central Drugs Standard Control Organisation (CDSCO) gave its approval followed by the recommendation of the Subject Expert Committee (SEC) that recommended both the vaccines for emergency use.

"After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation," said the DCGI.

It said that the Oxford vaccine has been found to be 70.42 per cent efficient. "M/s Serum and M/s Bharat Biotech vaccines have to be administered in two doses. All the three vaccines have to be stored at 2-8 degree Celsius," said the DCGI.

The third vaccine that is being referred to is Cadila Healthcare's candidate that has been approved for Phase 3 clinical trials.

The CDSCO met on January 1 and 2 and made recommendations for restricted emergency approval of the vaccines. The SEC consists of experts from fields of pulmonology, immunology, microbiology, pharmacology, paediatrics, internal medicine and more.

 

Asianet.in/NewsDesk: Asianet Online